. Author manuscript; available in PMC: 2020 Apr 28.

Published in final edited form as: Liver Transpl. 2019 Jan;25(1):14–24. doi: 10.1002/lt.25346

Table 1:

Patient demographics and clinical outcomes

	NASH (n=136)	ALD (n=129)	p-value
Age in years (SD)	60.2 (7.8)	53.7 (10.1)	<0.001
Male (%)	70 (52%)	89 (69%)	0.004
BMI, Kg/m² (SD)	34.9 (8.0)	27.6 (5.1)	0.001
MELD (SD)	15 (6.8)	17.6 (6.2)	<0.001
Decompensation pre-LT (%)
Hepatic encephalopathy	88 (65%)	92 (71%)	0.25
Ascites	99 (73%)	119 (92%)	<0.001
Variceal bleeding	35 (26%)	39 (30%)	0.41
Hepatorenal syndrome	12 (9%)	9 (7%)	0.58
Hospitalization pre-LT	56 (41%)	78 (61%)	0.002
LOS (days) (SD)	11.0 (10.7)	13.3 (13.6)	0.24
Delisted 1-year cumulative incidence (% [95% CI])	13.6% [7.9, 19.0]	28.3% [19.9, 35.8]	0.32
Frail (%)	51 (49%)	37 (34%)	0.026
Sarcopenia (%)	30 (22%)	60 (47%)	<0.001
Myosteatosis (%)	83 (62%)	74 (58%)	0.50
CT at time of LT evaluation
Visceral fat, cm2/m2, (SD)	74.9 (37.8)	46.1 (26.1)	<0.001
Muscle adipose, HU, (SD)	31.1 (8.6)	34.3 (8.4)	0.003
Muscle mass, cm2/m2 (SD)	51.6 (10.4)	48.3 (8.9)	0.008

^†

p-value from a Cox-proportional hazards model; LOS- length of stay